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Background: To investigate a prognostic role of gross tumor volume (GTV) changes on survival outcomes
following concurrent chemoradiotherapy (CCRT) in stage III non-small-cell lung cancer (NSCLC) patients.
Methods: We enrolled 191 patients with stage III NSCLC from 2001 to 2009 undergoing definitive CCRT. The GTV of
157 patients was delineated at the planning CT prior to CCRT and with a follow-up CT 1 month after CCRT. We
assessed the volumetric parameters of pre-treatment GTV (GTVpre) post-treatment GTV (GTVpost), and volume reduction
ratio of GTV (VRR). The primary endpoint was overall survival (OS) and secondary endpoints were progression-free
survival (PFS) and locoregional progression-free survival (LRPFS). The best cut-off value was defined as that which
exhibited the maximum difference between the two groups.
Results: The median follow-up duration was 52.7 months in surviving patients. Median survival, 3-year OS, PFS and
LRPFS rates were 25.5 months, 36.4%, 23.0%, and 45.0%, respectively. The selected cut-off values were 50 cm3 for GTVpre,
20 cm3 for GTVpost, and 50% for VRR. The smaller GTVpre and GTVpost values were associated with better OS (p < 0.001
and p = 0.015) and PFS (p = 0.001 and p = 0.004), respectively, upon univariate analysis. The higher VRR of > 50% was
associated with a trend toward poorer OS (p = 0.004) and PFS (p = 0.054). Upon multivariate analysis, smaller GTVpre
indicated significantly improved OS (p = 0.001), PFS (p = 0.013) and LRPFS (p = 0.002), while smaller GTVpost was
marginally significant for PFS (p = 0.086). Higher VRR was associated with a trend toward poorer OS (p = 0.075).
Conclusions: In patients with stage III NSCLC undergoing definitive CCRT, GTVpre was an independent prognostic factor
of survival. Notably, improved outcome was not correlated with higher VRR after short-term follow-up with CT alone.
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SurvivalBackground
Definitive radiotherapy with concurrent chemotherapy
(CCRT) has been the mainstay of treatment for unre-
sectable or medically inoperable stage III non-small cell
lung cancer (NSCLC), and offers a greater chance of sur-
vival compared with sequential chemoradiotherapy [1,2].* Correspondence: shmoon@ncc.re.kr
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unless otherwise stated.The American Joint Commission on Cancer (AJCC) TNM
staging system is widely used to estimate the prognosis of
patients treated with definitive radiotherapy (RT) for stage
III NSCLC but is less informative for radiation oncologists
[3-5]. The AJCC TNM staging system includes detailed
size criteria in the staging of NSCLC since the size of
primary tumor itself, as well as the anatomic location and
invasiveness of the primary lesion, is consistently related
to prognosis [4]. In patients with stage III NSCLC treated
with CCRT, the response rate may reflect sensitivity to
both RT and chemotherapy or tumor kinetics. However, it. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patients’ characteristics
Characteristics n (%)
Age (y) Median (range) 63 (range, 27–81)
Sex Male 137 (87%)
Female 20 (13%)
Performance ECOG 0 39 (25%)
ECOG 1 111 (71%)
ECOG 2 7 (4%)
Histology Squamous cell carcinoma 86 (55%)
Adenocarcinoma 52 (33%)
Large cell carcinoma 2 (1%)
NSCLC, NOS 17 (11%)








Stage IIIA 49 (31%)
IIIB 108 (69%)
Abbreviations: ECOG Eastern Cooperative Oncology Group, NSCLC Non-small-cell
lung cancer, NOS Not otherwise specified.
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changes after CCRT are associated with prognosis.
While a prognostic role for tumor volume in survival
of patients with definitive RT has been reported [6-12],
none of these studies investigated the effect of residual
tumor volume or tumor volume change during treat-
ment on the treatment outcome. In this retrospective
study, we performed volumetric survival analysis to
investigate the prognostic role of gross tumor volume
(GTV) before and after treatment on survival outcomes
in stage III NSCLC patients treated with CCRT.
Methods
A total of 191 patients with stage III NSCLC underwent
definitive CCRT from December 2001–January 2009 in
our institution. A diagnosis of NSCLC was histologically
confirmed and all patients re-staged with the 7th AJCC
TNM staging system [13]. All patients underwent pre-
treatment imaging work up, including chest radiographs
and computed tomography (CT). For the purpose of our
study, 22 patients were excluded due to loss of follow-up
immediately after completion of CCRT, incomplete RT
of < 50 Gy, or planned surgery following treatment. Add-
itionally, 12 patients whose initial tumor volume data
was not available to be reviewed due to technical errors
during image registration were excluded. Patient charac-
teristics are listed in Table 1.
Radiotherapy
Ninety percent of patients (n = 142) were treated with
three-dimensional conformal RT (3D-CRT). The remain-
der received intensity-modified radiotherapy (IMRT, n = 3)
or helical tomotherapy (n = 12). All treatments were based
on CT planning. The CT simulation was performed with
GE LightSpeed RT (GE Healthcare, Milwaukee, WI, USA)
or Picker CT-Simulator UltraZ (Philips Medical System,
Best, The Netherlands), and each scan slice had 3–5 mm
thickness. Patients were required to have shallow respir-
ation, and scanned from lower neck to upper abdomen
over 10 respiratory phases. The target volumes were
defined as follows: GTV, primary tumor(s) and involved
lymph node(s); clinical target volume (CTV), GTV +1 cm
for microscopic tumor extension; planning target volume
(PTV), CTV +5-15 mm margin. A minimum of 3–6
coplanar isocentric fields were designed for 3D-CRT and
IMRT with Pinnacle radiotherapy treatment planning
(RTP) systems (Philips Radiation Oncology Systems,
Milpitas, CA, USA) or the Eclipse RTP system, version 8.3
(Varian Medical System Inc., Palo Alto, CA, USA). The
Hi-Art Helical TomoTherapy RTP system, version 3.0
(TomoTherapy Inc., Madison, WI, USA) was used for
helical tomotherapy planning. The median daily dose and
total dose were 2 Gy (range, 1.8–2.4 Gy) and 63 Gy (range,
59.4–74 Gy), respectively. The 2 Gy equivalent total targetdoses were estimated as a median of 66.1 Gy (range, 57.3–
73.8 Gy), with the assumptions of an α/β ratio as 10 Gy,
effective doubling time as 5 days, and kick-off time of ac-
celerated repopulation as 14 days. The details of RT are
provided in Table 2.
Chemotherapy
Chemotherapy regimens administered during RT were as
follows (Table 2). Cisplatin (60 mg/m2 on days 1, 8, 29,
and 36) and etoposide (100 mg/m2 on days 1–5 and 29–
33) in 54 patients (34%), weekly carboplatin (area under
the curve = 2, intravenously over 30 min) and paclitaxel
(50 mg/m2 over 1 h) in 50 patients (32%), weekly cisplatin
(20 mg/m2 on days 1, 8, 29, and 36) plus paclitaxel
(50 mg/m2 over 1 h) in 36 patients (23%), and weekly cis-
platin (30 mg/m2 on days 1, 8, 29, and 36) and irrinotecan
(60 mg/m2) in 17 patients (11%).
Follow-up
Patients were regularly followed after the completion of
CCRT at 1 month, every 3 months for 2 years, and every
6 months thereafter. Follow-up examination routinely
included chest radiographs and chest CT. Generally, the
follow-up CT was scanned in a breath-holding period
with a less than 3 mm of thickness. Our instituional
policy has been to check short-term follow-up CT in













Cisplatin, Etoposide 54 (34)
Carboplatin, Paclitaxel 50 (32)
Cisplatin, Paclitaxel 36 (23)
Cisplatin, Irinotecan 17 (11)
Abbreviations: 3D-CRT Three-dimensional radiotherapy, IMRT Intensity-modulated
radiotherapy.
Figure 1 Kaplan-Meier survival curves for study patients.
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rence of radiation pneumonitis, because early radiation
pneumonitis usually gets evident on imaging after a few
months of RT completion [14].
Locoregional failure was defined as recurrence in the
irradiated lung or in the regional lymph nodes. Failure in
any other site was noted as distant metastasis. The Radi-
ation Therapy Oncology Group (RTOG) and European
Organization for Research and Treatment of Cancer
(EORTC) radiation morbidity criteria were used to grade
acute and late toxicities [15].
Volumetric parameters
GTV was delineated at planning CT just before CCRT
(GTVpre) and at the follow-up CT 1 month after CCRT
(GTVpost). To minimize confusion between disease and
pneumonitis, the follow-up CT 1 month after CCRT
was selected to delineate GTVpost. We registered all
image data in the Pinnacle RTP system for delineation.
The volume reduction ratio of GTV (VRR), implying the
short-term response rate, was defined as % (GTVpost –
GTVpre)/GTVpre.
For the accuracy and consistency, GTVs were delin-
eated by a single physician and reviewed by two add-
itional physicians. GTVpre were defined as primary and
involved lymph nodes in the original RT planning. The
criteria of involved lymph nodes were as follows:
pathologic confirmation or diameter of > 10 mm. When
18 F-fluorodeoxyglucose positron emission tomography
(FDG-PET) was scanned, standardized uptake values
were referred to delineate GTVpre. For example, small
lymph nodes might be considered to be involved if showedhigh uptake. To prevent over-estimation of GTVpre, CT
images in a single respiratory phase were used rather than
maximum intensity projection. We traced GTVpre in the
follow-up CT and delineated as GTVpost. In case of atelec-
tasis, tumor was distinguished from collapsed lung tissues
by using serially scanned CT images or FDG-PET.
Statistics
Kaplan-Meier analysis was used to estimate survival rate,
set the primary endpoint overall survival (OS), the sec-
ondary progression-free survival (PFS) and locoregional
progression-free survival (LRPFS). To compare survival
differences, the log-rank test and Cox’s regression model
were used for categorical and continuous variables,
respectively. The observed differences were regarded sta-
tistically significant if the p value was < 0.05, and as non-
significant trends or borderline significance if the p value
was < 0.1. Multivariate analysis was performed by incorp-
orating variables shown to be significant or borderline sig-
nificant in univariate analysis, in addition to well-known
prognostic factors. The Cox proportional-hazards model
was used to calculate hazard ratios (HR) in multivariate
analysis. All statistical analyses were performed using SPSS
version 18.0 (SPSS Inc., Chicago, IL).
Volumetric parameters were analyzed as both continu-
ous and categorical variables. Hypothetical candidate
cut-off values of GTVpre, GTVpost, and VRR with opti-
mal ranges were tested by the statistical method pro-
posed by Contal and O’Quigley [16], which is based on
the log-rank test. Thereafter, both the receiver operating
characteristic (ROC) curve and a maximal χ2 method were
used to identify the best cut-off values of volume parame-
ters using the software package R 2.13.0 (R Development
Core Team, Vienna, Austria, http://www.R-project.org). A
total of 20 categorical values, from 10 to 200 cm3 for
GTVpre and GTVpost were tested as candidates for the best
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Of the 157 patients, 79 patients (50%) had T1 and T2
tumors, and 78 patients (50%) had T3 and T4 tumors.
Eighty-six patients (55%) had squamous cell carcinoma
(SqCC), and 52 patients (33%) had adenocarcinoma
(ADC). At the time of diagnosis, 150 patients (96%) had
an Eastern Cooperative Oncology Group performance
status of 0 to 1. Patients’ characteristics are provided in
Table 1.Table 3 Univariate analysis of volumetric parameter cut-off v
Variable* n 3Y LRPFS (%) p†
Sex Male 137 41.6 0.2
Female 20 63.3
Age ≤ 60 y 65 41.3 0.5
> 60 y 92 47.9
ECOG 0 39 32.6 0.6
1-2 118 47.8
Histology SqCC 86 36.0 0.0
Others 71 56.3
ADC 52 52.5 0.1
Others 105 40.5
T stage 1-2 79 56.4 0.0
3-4 78 33.8
N stage 0-2 81 49.4 0.4
3 76 39.5
Stage IIIA 49 56.5 0.0
IIIB 108 39.8
GTVpre (Continuous) (95% CI) (1.001) (0.3
(HR) (0.999–1.002)
≤ 50 cm3 33 75.0 0.0
> 50 cm3 124 34.8
GTVpost (Continuous) (95% CI) (1.004) (0.1
(HR) (0.998–1.010)
≤ 20 cm3 68 53.3 0.1
> 20 cm3 89 36.7
VRR (Continuous) (95% CI) (1.011) (0.1
(HR) (0.997–1.025)
≤ 50% 21 68.2 0.0
>50% 136 40.6
Abbreviations: ADC Adenocarcinoma, CI Confidence interval, ECOG Eastern Cooperat
tumor volume, HR Harzard ratio, LRPFS locoregional progression-free survival rate, O
gross tumor volume.
*All variables are categorical, unless being noted as “continuous”.
†The log-rank test and the Cox proportional hazards model were used for categoricSurvival outcomes
The median follow-up time for all patients was 24.4 months
(range, 2.5–99.9 months) and for surviving patients was
52.7 months (range, 27.4–99.9 months). The median OS
was 25.5 months and the estimated 3-year OS rate was
36.4%. The 3-year PFS was 23% (median, 10.6 months)
and the 3-year LRPFS was 45.0% (median, 25.7 months),
as shown in Figure 1.
Univariate analysis of cut-off values for volumetric
parameters related to survival outcomes
The median values of GTVpre, GTVpost, and VRR were
96.7 cm3 (range, 9.7–1169.8), 25.7 cm3 (range, 1.87–249.1),
and 70.9% (range, 1.7–96.9), respectively. The distributionsalues compared to survival outcomes
3Y PFS (%) p† 3Y OS (%) p†
51 22.9 0.589 36.6 0.017
23.8 55.0
63 20.5 0.444 35.5 0.307
25.0 37.1
11 15.0 0.318 34.4 0.721
25.5 36.8
48 24.0 0.517 32.0 0.151
19.2 41.8
10 19.2 0.596 45.0 0.335
24.9 34.6
34 25.2 0.281 43.8 0.106
20.7 28.7
48 29.2 0.108 37.0 0.686
17.0 35.6
84 33.1 0.041 42.0 0.705
18.6 33.7
30) (1.003) (<0.001) (1.001) (0.019)
(1.002–1.004) (1.000–1.002)
01 42.5 0.001 65.7 < 0.001
17.1 28.4
89) (1.015) (<0.001) (1.006) (0.008)
(1.008–1.021) (1.002–1.011)
65 32.4 0.004 43.2 0.015
15.5 31.0
26) (1.008) (0.139) (1.013) (0.028)
(0.997–1.020) (1.001–1.025)
42 39.6 0.054 64.6 0.004
20.2 32.2
ive Oncology Group, GTVpre Initial gross tumor volume, GTVpost Follow-up gross
S Overall survival rate, SqCC Squamous cell carcinoma, VRR Reduction ratio of
al and continuous variables, respectively.
Figure 2 Comparison of overall survival curves according to
gross tumor volume: (a) pre-treatment, (b) post-treatment,
(c) volume reduction ratio.
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cept VRR (Additional file 1: Figure S1). Through statistical
processing of the ROC curve and the maximal χ2 test de-
scribed above, possible cut-off values were estimated as 50
or 60 cm3 for GTVpre, 10 or 20 cm
3 for GTVpost, and 50
or 60% for VRR. The ideal cut-off value was selected from
the maximum difference between the two groups as
50 cm3 for GTVpre, 20 cm
3 for GTVpost, and 50% for VRR.
The results of univariate analyses of clinical and volu-
metric factors with OS, PFS and LRPFS are shown in
Table 3. Females had better OS outcomes than males
(p = 0.017) and patients with stage IIIA disease had
better PFS than patients with stage IIIB (p = 0.041). The
LRPFS of patients with squamous histology (p = 0.048)
and T3-4 (p = 0.034) was inferior to that of patients
with non-squamous histology and T1-2, respectively.
Patients with smaller GTVpre had significantly better OS
(p < 0.001), PFS (p = 0.001) and LRPFS (p = 0.001). Smaller
GTVpost was also indicative of better OS (p = 0.015) and
PFS (p = 0.004). Patients with higher VRR had worse OS
(p = 0.004). The OS curves related to volumetric parame-
ters are shown in Figure 2.
Multivariate analysis of cut-off values for volumetric
parameters related to survival outcomes
Based on the results of the univariate analyses, we per-
formed a multivariate analysis with a stepwise backward
selection procedure, incorporating clinical variables and
categorical volumetric parameters (Table 4). Smaller
GTVpre was found to be the only significant prognostic
factor of better LRPFS (HR = 2.926; p = 0.002), PFS
(HR = 2.001; p = 0.013), and OS (HR = 2.763; p = 0.001),
while a smaller GTVpost tended to be a prognostic fac-
tor of better PFS (HR = 1.467; p = 0.086). Higher VRR
was marginally significant for poorer OS (HR = 1.895;
p = 0.075). Squamous histology also tended to predict
a poorer PFS (HR = 1.455; p = 0.061).
Toxicity
During treatment, grade III or IV hematologic adverse
events were noted in 26 patients; no life-threatening
events were recorded. Radiation esophagitis developed
in 146 patients (42% with grade I, 46% grade 2, and 12%
grade 3). A total of 143 patients experienced radiation
pneumonitis (54% with grade I, 38% grade 2, 4% grade 3
and 3% grade IV). In five patients, treatment-related
pneumonitis was aggravated; these individuals ultimately
succumbed 6 months after treatment completion.
Discussion
Several volumetric studies have been conducted to
evaluate initial GTV as a prognostic factor in patients
with NSCLC who underwent definitive RT [6-12]. How-
ever, the prognostic role of residual tumor volume ortumor response after treatment was assessed only in tri-
als of induction therapy for NSCLC [8,17,18], not defini-
tive CCRT. To our knowledge, the present study is the
first to evaluate the prognostic role of volumetric param-
eters and include GTVpre, GTVpost, and VRR in patients
with NSCLC who underwent definitive CCRT.
Table 4 Multivariate analysis of volumetric parameter cut-off values compared to survival outcomes
LRPFS PFS OS
HR (95% CI) p HR (95% CI) p HR (95% CI) p
Sex (Male vs. Female) NS NS NS
Histology (SqCC vs. Others) NS 1.455 (0.983–2.155) 0.061 NS
T stage (T1-T2 vs. T3-T4) NS NS NS
N stage (N0-N2 vs. N3) NS NS NS
Stage (IIIA vs. IIIB) NS NS NS
GTVpre (≤ 50 cm
3 vs. > 50 cm3) 2.926 (1.495–5.726) 0.002 2.001 (1.159–3.454) 0.013 2.763 (1.552–4.919) 0.001
GTVpost (≤ 20 cm
3 vs. > 20 cm3) NS 1.467 (0.947–2.273) 0.086 NS
VRR (≤ 50% vs. > 50%) NS NS 1.895 (0.937–3.832) 0.075
Abbreviations: CI Confidence interval, GTVpre Initial gross tumor volume CT, GTVpost follow-up gross tumor volume, HR Hazard ratio, LRPFS Locoregional progression-free
survival rate, NS No significance, OS Overall survival rate, PFS Progression-free survival rate, SqCC Squamous cell carcinoma, VRR Reduction ratio of gross tumor volume.
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factor of survival in patients with CCRT for locally
advanced NSCLC, which is consistent with previous re-
ports. In a secondary analysis of the RTOG 93–11 phase
I-II radiation dose-escalation study by Werner-Wasik
et al. [7], patients with larger GTV, defined as the sum
of the volumes of the primary tumor and involved lymph
nodes, had a shorter median survival time and PFS than
patients with smaller GTV. Basaki et al. [10] also evalu-
ated the impact of tumor volume on OS in stage III
NSCLC patients (n = 71) treated with definitive RT using
sequential or concurrent chemotherapy, and found that
both the total tumor volume and the primary tumor
volume were significant, while the nodal volume was
not. In a study by Alexander et al. [11], both tumor and
nodal volume were associated with OS and local control,
but not with distant metastasis in patients with stage III
NSCLC (n = 107) treated by chemoradiotherapy with or
without surgery.
Current evidence of the prognostic significance of
GTVpre indicates that the larger the entire tumor bur-
den, the more difficult it is to achieve a log cell kill due
to the quantity of cancer cells to be destroyed and the
higher proportion of radio-resistant area. Several studies
segregated nodal volume from the entire tumor volume
with the hypothesis that volumes of primary tumor and
involved lymph nodes might represent local and sys-
temic NSCLC disease, respectively. Nodal volume might
provide additional information to the N stage; however,
the prognostic role of nodal volume is controversial
[4,10,11]. In the current study, we did not perform
subgroup analysis of nodal volume in GTVpre, because
segregated nodal volume delineation was difficult in a
proportion of patients due to lymph nodes conglomer-
ated with primary tumor. To evaluate the prognostic
role of primary tumor and nodal volumes, fractional
delineation using an advanced imaging technique, such
as FDG-PET, might be necessary [19,20].Although Yamane et al. [21] suggested the area of
residual tumor after neoadjuvant therapy as a prognostic
factor, GTVpost in our study was not significantly associ-
ated with OS in multivariate analysis, despite a trend
toward improved PFS. The short-term response rate has
frequently been used as a surrogate marker for survival
in novel oncology agent clinical trials. However, there is
little evidence of the influence of induction chemother-
apy response on survival [17,22,23]. In contrast, the
short-term response rate, evaluated 4–6 weeks after in-
duction CCRT followed by surgical resection, has been
reported as 35–66%, suggesting that the complete patho-
logical response is a significant predictor of prognosis
[24-27]. At this point, it is unclear whether a better
short-term response after definitive CCRT leads to im-
proved prognosis. However, it is known that if surgery is
technically feasible, it can benefit a small proportion of
patients.
Based on this, it is notable that a VRR > 50% after de-
finitive CCRT had a negative impact on OS in univariate
analysis and a similar trend in multivariate analysis.
Since the cut-off point of VRR in our study was 50%,
which is also the cut-off value dividing partial response
and stable disease in the conventional response criteria
of the World Health Organization [28] that measures
volume bi-dimensionally, better-responding patients after
short-term follow up were not guaranteed to have an im-
proved outcome without surgery in our study. Our inter-
esting finding may be reasonable, considering GTVpost
contains viable residual tumor as well as radiation injury.
We used CT alone to delineate GTVpost, however, CT has
a major restriction to distinguish persistent or recurrent
tumor from treatment-induced changes early after the
completion of RT [14]. It appears that the addition of
FDG-PET to CT is superior to CT alone in the evaluation
of persistent or recurrent tumor in patients undergoing
RT for NSCLC, as well as in the delineation of primary
lesion [29-31]. Therefore, our unexpected finding of VRR
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ation at certain time point may be ambiguous with CT
alone, so functional imaging technique, such as FDG-PET,
is a reasonable complement for early response assessment.
In NSCLC, treatment sensitivity or failure patterns differ
between squamous cell carcinoma (SqCC) and adeno-
carcinoma (ADC), with either surgery or RT [32-34].
Ishikawa et al. [33] analyzed the recurrence pattern and
survival of patients with stage I NSCLC treated with de-
finitive RT. There was no significant difference in survival;
however, the 5-year primary control rate of SqCC was
worse than that of ADC (62 vs. 88%, p = 0.03), and the 5-
year metastasis-free survival rate of SqCC was better than
that of ADC (88.2 vs. 53.0%, p = 0.005). In the current
study, patients with SqCC had worse LRPFS (p = 0.048),
which was not significant in multivariate analysis.
Our findings have clinical implications, since we
analyzed possible associations between all volumetric
parameters incorporating GTVpre, GTVpost and the VRR
in definitive CCRT with survival outcomes. Furthermore,
to minimize inter-observer variation attributed to vari-
ability in target delineation, GTVpre and GTVpost were
defined by a single physician, and consistencies of con-
tours were supervised by two physicians. Target delinea-
tion method of this study, as described above, could
contribute to decrease inter-observer variations, also.
Despite this, there are some limitations. For example,
the patient population was not homogenous in terms of
RT dose fractionation, planning technique, and chemo-
therapy regimens since the data were not extracted from
prospective clinical trials. It was also difficult to evaluate
the effect of salvage treatment on the outcome of
patients with disease progression after definitive CCRT.
Additionally, this retrospective study did not use FDG-
PET/CT for routine surveillance, which may be helpful
to assess early response of tumor.
In conclusion, smaller GTVpre was an independent
prognostic factor of better prognosis in patients with
stage III NSCLC treated with definitive CCRT. GTVpost
did not have association with survival on the multivari-
ate analysis. Notably, improved outcome was not corre-
lated with > 50% VRR after short-term follow-up with
CT alone. Our findings of GTVpost and VRR, in NSCLC
patients having definitive CCRT, should be clarified with a
prospective study of short-term response assessment using
functional imaging technique, such as FDG-PET/CT.
Conclusions
We confirmed that smaller GTVpre was associated with
better survival. Interestingly, GTVpost did not have an as-
sociation with survival on the multivariate analysis; higher
VRR had a trend of poorer survival. GTVpre is a significant
prognostic factor for survival. Short-term follow-up using
CT alone may not be enough for response assessment inNSCLC patents having definitive CCRT. A prospective
study using functional imaging modality is needed to
evaluate the prognostic role of early response assessment
in NSCLC patients having definitive CCRT.
Additional file
Additional file 1: Figure S1. Gross tumor volume has a normal
distribution on natural logarithmic scale: (a) pre-treatment, (b) post-treatment.
Volume reduction ratio is not normally distributed (c).
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